93 related articles for article (PubMed ID: 25665320)
21. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
[TBL] [Abstract][Full Text] [Related]
22. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
23. TUR and chemotherapy or radiotherapy for invasive bladder cancer.
Hall RR; Roberts T; Powell PH; Marsh MM
Prog Clin Biol Res; 1988; 260():605-12. PubMed ID: 3129740
[No Abstract] [Full Text] [Related]
24. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer.
Colvett KT; Althausen AF; Bassil B; Heney NM; McGovern FV; Young HH; Kaufman DS; Zietman AL; Shipley WU
J Surg Oncol; 1996 Nov; 63(3):201-8. PubMed ID: 8944067
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy and chemotherapy for invasive bladder cancer.
Javle M; Raghavan D
Cancer Surv; 1998; 31():149-60. PubMed ID: 15281322
[TBL] [Abstract][Full Text] [Related]
26. Current status of radiation therapy and combined-modality treatment for bladder cancer.
Rödel C
Strahlenther Onkol; 2004 Nov; 180(11):701-9. PubMed ID: 15549188
[TBL] [Abstract][Full Text] [Related]
27. [Response and progression-free survival in T2 to T4 bladder tumors treated with trimodality therapy with bladder preservation].
Rincón Mayans A; Rosell Costa D; Zudaire Bergera JJ; Rioja Zuazu J; Barba Abad J; Tolosa Eizaguirre E; Romero Vargas L; Pascual Piedrola I
Actas Urol Esp; 2010 Oct; 34(9):775-80. PubMed ID: 20843454
[TBL] [Abstract][Full Text] [Related]
28. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
Gray PJ; Fedewa SA; Shipley WU; Efstathiou JA; Lin CC; Zietman AL; Virgo KS
Eur Urol; 2013 May; 63(5):823-9. PubMed ID: 23200811
[TBL] [Abstract][Full Text] [Related]
29. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.
Zietman AL; Sacco D; Skowronski U; Gomery P; Kaufman DS; Clark JA; Talcott JA; Shipley WU
J Urol; 2003 Nov; 170(5):1772-6. PubMed ID: 14532773
[TBL] [Abstract][Full Text] [Related]
30. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
[TBL] [Abstract][Full Text] [Related]
31. Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy.
Sanguineti G; Orsatti M; Sormani MP; Canobbio L; Curotto A; Tognoni P; Giudici S; Franzone P; Boccardo F; Vitale V
Cancer J Sci Am; 1997; 3(4):213-23. PubMed ID: 9263627
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic options and treatment of muscle invasive bladder cancer.
O'Connor RC; Alsikafi NF; Steinberg GD
Expert Rev Anticancer Ther; 2001 Dec; 1(4):511-22. PubMed ID: 12113083
[TBL] [Abstract][Full Text] [Related]
33. [The role of preserving therapy of invasive cancer of the urinary bladder].
Matveev BP; Sallum SD; Kamolov BSh; Figurin KM; Matveev VB; Volkova MI
Urologiia; 2005; (6):3-6. PubMed ID: 16419470
[TBL] [Abstract][Full Text] [Related]
34. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
35. [Chemoradiotherapy for muscle-invasive cancer: methods, surveillance and results. An update from the cancer committee of the French National Association of Urology].
Quintens H; Roupret M; Larré S; Neuzillet Y; Pignot G; Compérat E; Wallerand H; Houédé N; Roy C; Soulié M; Pfister C;
Prog Urol; 2012 Jan; 22(1):13-6. PubMed ID: 22196000
[TBL] [Abstract][Full Text] [Related]
36. Candidate quality of care indicators for localized bladder cancer.
Cooperberg MR; Porter MP; Konety BR
Urol Oncol; 2009; 27(4):435-42. PubMed ID: 19573775
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
38. [Variations in the treatment of non-metastatic muscle-invasive bladder carcinoma].
Krijnen P; Bos MM; Kloosterman-Boele WM; Bevers RF
Ned Tijdschr Geneeskd; 2011; 155():A2703. PubMed ID: 21447215
[TBL] [Abstract][Full Text] [Related]
39. Editorial comment from Dr Koga to local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder.
Koga F
Int J Urol; 2013 Aug; 20(8):785-6. PubMed ID: 23231681
[No Abstract] [Full Text] [Related]
40. Editorial comment from Dr Ismaili to local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder.
Ismaili N
Int J Urol; 2013 Aug; 20(8):784-5. PubMed ID: 23231637
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
